Subgroups of Sjögren syndrome patients according to serological profiles

Journal of Autoimmunity

Volumn 39, Issue 1-2, 2012, Pages 15-26

  Bournia, Vasiliki Kalliopi ^a   Vlachoyiannopoulos, Panayiotis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anti carbonic anhydrase; Anti CCP; Anti centromere antibodies; Anti La SSB; Anti mitochondrial antibodies; Anti muscarinic; Anti nuclear antibodies; Anti Ro SSA; Anti smooth muscle antibodies; Autoantibodies; Cryoglobulins; Rheumatoid factor; Sj gren syndrome

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARBONATE DEHYDRATASE; CENTROMERE ANTIBODY; CENTROMERE PROTEIN A; CENTROMERE PROTEIN B; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CRYOGLOBULIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; HLA DQ1 ANTIGEN; HLA DQ2 ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LA ANTIBODY; MESSENGER RNA; MITOCHONDRION ANTIBODY; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC M4 RECEPTOR; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SMOOTH MUSCLE ANTIBODY; UNINDEXED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTHRITIS; ARTICLE; AUTOIMMUNE HEPATITIS; BINDING SITE; CANCER RISK; CHRONIC LIVER DISEASE; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; DNA RNA HYBRIDIZATION; ENZYME ACTIVITY; EXOCRINE GLAND; FEVER; FOLLOW UP; GAMMOPATHY; HEPATITIS C; HLA SYSTEM; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPOCOMPLEMENTEMIA; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY TUBULE ACIDOSIS; LEUKOPENIA; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; NEPHELOMETRY; NEUROTRANSMISSION; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAYNAUD PHENOMENON; RING FINGER MOTIF; RNA BINDING; RNA FOLDING; SALIVARY GLAND BIOPSY; SALIVATION; SCHIRMER TEST; SEROLOGY; SJOEGREN SYNDROME; SYNOVITIS; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; UBIQUITINATION; URINE PH; VASCULITIS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; RHEUMATOID FACTOR; RIBONUCLEOPROTEINS; RNA, SMALL CYTOPLASMIC; SJOGREN'S SYNDROME;

EID: 84862487042     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.03.001     Document Type: Article

References (127)

1. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010, 9:A305-A310.
2. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T.H. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
3. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine 2009, 88:284-293.
4. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H., Alexander E., Carsons S., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002, 61:554-558.
5. Nardi N., Brito-Zeron P., Ramos-Casals M., Aguilo S., Cervera R., Ingelmo M., et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjogren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006, 25:341-346.
6. Routsias J.G., Tzioufas A.G. Sjogren's syndrome-study of autoantigens and autoantibodies. Clin Rev Allergy Immunol 2007, 32:238-251.
7. Simons F.H., Pruijn G.J., van Venrooij W.J. Analysis of the intracellular localization and assembly of Ro ribonucleoprotein particles by microinjection into Xenopus laevis oocytes. J Cell Biol 1994, 125:981-988.
8. Farris A.D., Koelsch G., Pruijn G.J., van Venrooij W.J., Harley J.B. Conserved features of Y RNAs revealed by automated phylogenetic secondary structure analysis. Nucleic Acids Res 1999, 27:1070-1078.
9. Christov C.P., Gardiner T.J., Szuts D., Krude T. Functional requirement of noncoding Y RNAs for human chromosomal DNA replication. Mol Cell Biol 2006, 26:6993-7004.
10. Labbe J.C., Jannatipour M., Rokeach L.A. The Caenorhabditis elegans rop-1 gene encodes the homologue of the human 60-kDa Ro autoantigen. Gene 1995, 167:227-231.
11. Chen X., Wolin S.L. The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity. J Mol Med (Berl) 2004, 82:232-239.
12. Stein A.J., Fuchs G., Fu C., Wolin S.L., Reinisch K.M. Structural insights into RNA quality control: the Ro autoantigen binds misfolded RNAs via its central cavity. Cell 2005, 121:529-539.
13. Ottosson L., Hennig J., Espinosa A., Brauner S., Wahren-Herlenius M., Sunnerhagen M. Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjogren's syndrome. Mol Immunol 2006, 43:588-598.
14. Espinosa A., Zhou W., Ek M., Hedlund M., Brauner S., Popovic K., et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006, 176:6277-6285.
15. Higgs R., Ni Gabhann J., Ben Larbi N., Breen E.P., Fitzgerald K.A., Jefferies C.A. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 2008, 181:1780-1786.
16. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, et al. Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One;5:e11776.
17. Kong H.J., Anderson D.E., Lee C.H., Jang M.K., Tamura T., Tailor P., et al. Cutting edge: autoantigen Ro52 is an Interferon Inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 2007, 179:26-30.
18. Bousquet-Antonelli C., Deragon J.M. A comprehensive analysis of the La-motif protein superfamily. RNA 2009, 15:750-764.
19. Maraia R.J. Transcription termination factor La is also an initiation factor for RNA polymerase III. Proc Natl Acad Sci U S A 1996, 93:3383-3387.
20. Routsias J.G., Tzioufas A.G. B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: tools to study the regulation of the autoimmune response. J Autoimmun 2010, 35:256-264.
21. ter Borg E.-J., Risselada A.P., Kelder J.C. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren's syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum 2011, 40:547-551.
22. Ramos-Casals M., Solans R., Rosas J., Camps M.T., Gil A., Del Pino-Montes J., et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008, 87:210-219.
23. Fauchais A.L., Martel C., Gondran G., Lambert M., Launay D., Jauberteau M.O., et al. Immunological profile in primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 2010, 9:595-599.
24. Martel C., Gondran G., Launay D., Lalloué F., Palat S., Lambert M., et al. Active immunological profile is associated with systemic Sjogren's syndrome. J Clin Immunol 2011.
25. Locht H., Pelck R., Manthorpe R. Clinical manifestations correlated to the prevalence of autoantibodies in a large (n = 321) cohort of patients with primary Sjogren's syndrome: a comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria. Autoimmun Rev 2005, 4:276-281.
26. Manoussakis M.N., Kistis K.G., Liu X., Aidinis V., Guialis A., Moutsopoulos H.M. Detection of anti-ro(ssa) antibodies in autoimmune diseases: comparison of five methods. Rheumatology 1993, 32:449-455.
27. Barcellos K.S., Nonogaki S., Enokihara M.M., Teixeira M.S., Andrade L.E. Differential expression of Ro/SSA 60 kDa and La/SSB, but not Ro/SSA 52 kDa, mRNA and protein in minor salivary glands from patients with primary Sjogren's syndrome. J Rheumatol 2007, 34:1283-1292.
28. Tzioufas A.G., Hantoumi I., Polihronis M., Xanthou G., Moutsopoulos H.M. Autoantibodies to La/SSB in patients with primary Sjogren's syndrome (pSS) are associated with upregulation of La/SSB mRNA in minor salivary gland biopsies (MSGs). J Autoimmun 1999, 13:429-434.
29. Tengner P., Halse A.K., Haga H.J., Jonsson R., Wahren-Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren's syndrome. Arthritis Rheum 1998, 41:2238-2248.
30. Horsfall A.C., Rose L.M., Maini R.N. Autoantibody synthesis in salivary glands of Sjogren's syndrome patients. J Autoimmun 1989, 2:559-568.
31. Hammi A.R., Al-Hashimi I.H., Nunn M.E., Zipp M. Assessment of SS-A and SS-B in parotid saliva of patients with Sjogren's syndrome. J Oral Pathol Med 2005, 34:198-203.
32. Davidson B.K., Kelly C.A., Griffiths I.D. Primary Sjogren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 1999, 38:245-253.
33. Kessel A., Toubi E., Rozenbaum M., Zisman D., Sabo E., Rosner I. Sjogren's syndrome in the community: can serology replace salivary gland biopsy?. Rheumatol Int 2006, 26:337-339.
34. Tzioufas A.G., Wassmuth R., Dafni U.G., Guialis A., Haga H.J., Isenberg D.A., et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. Ann Rheum Dis 2002, 61:398-404.
35. Goeb V., Salle V., Duhaut P., Jouen F., Smail A., Ducroix J.P., et al. Clinical significance of autoantibodies recognizing Sjogren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjogren's syndrome. Clin Exp Immunol 2007, 148:281-287.
36. Toker E., Yavuz S., Direskeneli H. Anti-Ro/SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjogren's syndrome. Br J Ophthalmol 2004, 88:384-387.
37. Gerli R., Muscat C., Giansanti M., Danieli M.G., Sciuto M., Gabrielli A., et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjogren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol 1997, 36:969-975.
38. Jonsson M.V., Skarstein K., Jonsson R., Brun J.G. Serological implications of germinal center-like structures in primary Sjogren's syndrome. J Rheumatol 2007, 34:2044-2049.
39. Brucato A., Cimaz R., Caporali R., Ramoni V., Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011, 40:27-41.
40. Jaeggi E., Laskin C., Hamilton R., Kingdom J., Silverman E. The Importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus: a Prospective study of 186 antibody-Exposed Fetuses and Infants. J Am Coll Cardiol 2010, 55:2778-2784.
41. Harley J.B., Reichlin M., Arnett F.C., Alexander E.L., Bias W.B., Provost T.T. Gene interaction at HLA-DQ enhances autoantibody production in primary Sjogren's syndrome. Science 1986, 232:1145-1147.
42. Gottenberg J.E., Busson M., Loiseau P., Cohen-Solal J., Lepage V., Charron D., et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 2003, 48:2240-2245.
43. Huo A.P., Lin K.C., Chou C.T. Predictive and prognostic value of antinuclear antibodies and rheumatoid factor in primary Sjogren's syndrome. Int J Rheum Dis 2010, 13:39-47.
44. Karabulut G., Kitapcioglu G., Inal V., Kalfa M., Yargucu F., Keser G., et al. Cigarette smoking in primary Sjogren's syndrome: positive association only with ANA positivity. Mod Rheumatol 2011.
45. Aupperle K.R., Alsalameh S., Stock K.P., Burmester G.R., Kalden J.R. Comparison of rheumatoid test procedures-value and critical interpretation of sensitivity and specificity and their effect on pre-test and post-test probability. Z Rheumatol 1996, 55:158-167.
46. Pertovaara M., Pukkala E., Laippala P., Miettinen A., Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001, 60:467-472.
47. Peen E., Mellbye O.J., Haga H.J. IgA rheumatoid factor in primary Sjögren's syndrome. Scand J Rheumatol 2009, 38:46-49.
48. Tedeschi A., Baratè C., Minola E., Morra E. Cryoglobulinemia. Blood Rev 2007, 21:183-200.
49. Skopouli F.N., Dafni U., Ioannidis J.P.A., Moutsopoulos H.M. Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
50. Brito-Zerón P., Ramos-Casals M., Bove A., Sentis J., Font J. Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology 2007, 46:1359-1362.
51. Gottenberg J.E., Mignot S., Nicaise-Rolland P., Cohen-Solal J., Aucouturier F., Goetz J., et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005, 64:114-117.
52. Tobon G.J., Correa P.A., Anaya J.M. Anti-cyclic citrullinated peptide antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005, 64:791-792.
53. Atzeni F., Sarzi-Puttini P., Lama N., Bonacci E., Bobbio-Pallavicini F., Montecucco C., et al. Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008, 10:R51.
54. Iwamoto N., Kawakami A., Tamai M., Fujikawa K., Arima K., Aramaki T., et al. Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies. J Rheumatol 2009, 36:113-115.
55. Barcelos F., Abreu I., Patto J.V., Trindade H., Teixeira A. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjogren's syndrome. Acta Reumatol Port 2009, 34:608-612.
56. Niewold T.B., Harrison M.J., Paget S.A. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 2007, 100:193-201.
57. Mackay I.R. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med 1958, 258:185-188.
58. Patel D., Egner W., Gleeson D., Wild G., Ward A. Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay is potentially less specific than by immunofluorescence. Ann Clin Biochem 2002, 39:304-307.
59. Bogdanos D.P., Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011, 412:502-512.
60. Strassburg C.P., Manns M.P. Autoimmune tests in primary biliary cirrhosis. Best Pract Res Clin Gastroenterol 2000, 14:585-599.
61. Tsianos E.V., Hoofnagle J.H., Fox P.C., Alspaugh M., Jones E.A., Schafer D.F., et al. Sjogren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990, 11:730-734.
62. Hansen B.U., Lindgren S., Eriksson S., Henricsson V., Larsson å., Manthorpe R., et al. Clinical and immunological features of Sjögren's syndrome in patients with primary biliary cirrhosis with Emphasis on focal sialadenitis. Acta Med Scand 1988, 224:611-619.
63. Hatzis G.S., Fragoulis G.E., Karatzaferis A., Delladetsima I., Barbatis C., Moutsopoulos H.M. Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren's syndrome. J Rheumatol 2008, 35:2012-2016.
64. Csepregi A., Szodoray P., Zeher M. Do autoantibodies predict autoimmune liver disease in primary Sjogren's syndrome? Data of 180 patients upon a 5 year follow-up. Scand J Immunol 2002, 56:623-629.
65. Lindgren S., Manthorpe R., Eriksson S. Autoimmune liver disease in patients with primary Sjogren's syndrome. J Hepatol 1994, 20:354-358.
66. Skopouli F.N., Barbatis C., Moutsopoulos H.M. Liver involvement in primary Sjogren's syndrome. Br J Rheumatol 1994, 33:745-748.
67. Fujikura S., Davis P.A., Prindiville T., Leung P., Fox R.I., Gershwin M.E. Sjogren's syndrome and primary biliary cirrhosis: presence of autoantibodies to purified mitochondrial 2-OXO acid dehydrogenases. J Rheumatol 1990, 17:1453-1457.
68. Zurgil N., Bakimer R., Moutsopoulos H.M., Tzioufas A.G., Youinou P., Isenberg D.A., et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol 1992, 12:201-209.
69. Manthorpe R., Permin H., Tage-Jensen U. Auto-antibodies in Sjogren's syndrome. With special reference to liver-cell membrane antibody (LMA). Scand J Rheumatol 1979, 8:168-172.
70. Ramos-Casals M., Sanchez-Tapias J.M., Pares A., Forns X., Brito-Zeron P., Nardi N., et al. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjogren's syndrome. J Rheumatol 2006, 33:1593-1599.
71. Mitsias D.I., Kapsogeorgou E.K., Moutsopoulos H.M. Sjogren's syndrome: why autoimmune epithelitis?. Oral Dis 2006, 12:523-532.
72. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
73. Karp J.K., Akpek E.K., Anders R.A. Autoimmune hepatitis in patients with primary Sjogren's syndrome: a series of two-hundred and two patients. Int J Clin Exp Pathol 2010, 3:582-586.
74. Matsumoto T., Morizane T., Aoki Y., Yamasaki S., Nakajima M., Enomoto N., et al. Autoimmune hepatitis in primary Sjögren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjögren's syndrome. Pathol Int 2005, 55:70-76.
75. Hsu T.-C., Chang C.-H., Lin M.-C., Liu S.-T., Yen T., Tsay G. Anti-CENP-H antibodies in patients with Sjogren's syndrome. Rheumatol Int 2006, 26:298-303.
76. González-Buitrago J.M., González C., Hernando M., Carrasco R., Sánchez A., Navajo J.A., et al. Antibodies to centromere antigens measured by an automated enzyme immunoassay. Clin Chim Acta 2003, 328:135-138.
77. Mahler M., You D., Baron M., Taillefer S.S., Hudson M., Fritzler M.J. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 2011, 412:1937-1943.
78. Renier G., Le Normand I., Chevailler A., Verret J.L., Renier J.C., Hurez D. Anti-centromere antibodies. Study of 67 positive sera. Rev Med Interne 1992, 13:413-414. 7-8.
79. Vlachoyiannopoulos P.G., Drosos A.A., Wiik A., Moutsopoulos H.M. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Rheumatology 1993, 32:297-301.
80. Miyawaki S., Asanuma H., Nishiyama S., Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005, 32:1488-1494.
81. Bournia V.K., Diamanti K.D., Vlachoyiannopoulos P.G., Moutsopoulos H.M. Anticentromere antibody positive Sjogren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010, 12:R47.
82. Salliot C., Gottenberg J.E., Bengoufa D., Desmoulins F., Miceli-Richard C., Mariette X. Anticentromere antibodies identify patients with Sjogren's syndrome and autoimmune overlap syndrome. J Rheumatol 2007, 34:2253-2258.
83. Caramaschi P., Biasi D., Carletto A., Manzo T., Randon M., Zeminian S., et al. Sjogren's syndrome with anticentromere antibodies. Rev Rhum Engl Ed 1997, 64:785-788.
84. Katano K., Kawano M., Koni I., Sugai S., Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjogren's syndrome. J Rheumatol 2001, 28:2238-2244.
85. Nakamura H., Kawakami A., Hayashi T., Iwamoto N., Okada A., Tamai M., et al. Anti-centromere antibody-seropositive Sjogren's syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord 2010, 11:140.
86. Kitagawa T., Shibasaki K., Toya S. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren's syndrome. Clin Rheumatol 2011.
87. Gelber A.C., Pillemer S.R., Baum B.J., Wigley F.M., Hummers L.K., Morris S., et al. Distinct recognition of antibodies to centromere proteins in primary Sjögren's syndrome compared with limited scleroderma. Ann Rheum Dis 2006, 65:1028-1032.
88. Ramos-Casals M., Nardi N., Brito-Zerón P., Aguiló S., Gil V., Delgado G., et al. Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006, 35:312-321.
89. Gulati D., Kushner I., File E., Magrey M. Primary Sjogren's syndrome with anticentromere antibodies-a clinically distinct subset. Clin Rheumatol 2010, 29:789-791.
90. Pertovaara M., Bootorabi F., Kuuslahti M., Pasternack A., Parkkila S. Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2011, 50:1453-1457.
91. Ono M., Watanabe K., Miyashita Y., Inagaki Y., Ueki H. A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases. J Dermatol Sci 1999, 21:183-186.
92. Itoh Y., Reichlin M. Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 1992, 35:73-82.
93. Ueno Y., Ishii M., Igarashi T., Mano Y., Yahagi K., Kisara N., et al. Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds. Hepatol Res 2001, 20:18-27.
94. Gordon S.C., Quattrociocchi-Longe T.M., Khan B.A., Kodali V.P., Chen J., Silverman A.L., et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995, 108:1802-1809.
95. Alver A., Mentese A., Karahan S.C., Erem C., Keha E.E., Arikan M.K., et al. Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease. Exp Clin Endocrinol Diabetes 2007, 115:287-291.
96. Nishimori I., Bratanova T., Toshkov I., Caffrey T., Mogaki M., Shibata Y., et al. Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. J Immunol 1995, 154:4865-4873.
97. Ren H., Wang W.-M., Chen X.-N., Zhang W., Pan X.-X., Wang X.-L., et al. Renal involvement and followup of 130 patients with primary Sjögren's syndrome. J Rheumatol 2008, 35:278-284.
98. Sly W.S., Hewett-Emmett D., Whyte M.P., Yu Y.S., Tashian R.E. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 1983, 80:2752-2756.
99. Takemoto F., Katori H., Sawa N., Hoshino J., Suwabe T., Sogawa Y., et al. Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome. Nephron Physiol 2007, 106:p63-p68.
100. Eglen R.M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006, 26:219-233.
101. Ishii M., Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharm Des 2006, 12:3573-3581.
102. Iwabuchi Y., Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen Pharmacol 1994, 25:123-129.
103. Nakamura T., Matsui M., Uchida K., Futatsugi A., Kusakawa S., Matsumoto N., et al. M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 2004, 558:561-575.
104. Bacman S., Sterin-Borda L., Camusso J.J., Arana R., Hubscher O., Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996, 104:454-459.
105. Iga Y., Arisawa H., Ogane N., Saito Y., Tomizuka T., Nakagawa-Yagi Y., et al. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 1998, 78:373-380.
106. Robinson C.P., Brayer J., Yamachika S., Esch T.R., Peck A.B., Stewart C.A., et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 1998, 95:7538-7543.
107. Nguyen K.H.T., Brayer J., Cha S., Diggs S., Yasunari U., Hilal G., et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000, 43:2297-2306.
108. Li J., Ha Y.M., Ku N.Y., Choi S.Y., Lee S.J., Oh S.B., et al. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. Lab Invest 2004, 84:1430-1438.
109. Waterman S.A., Gordon T.P., Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2000, 43:1647-1654.
110. Wang F., Jackson M.W., Maughan V., Cavill D., Smith A.J., Waterman S.A., et al. Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 2004, 50:3637-3645.
111. Cavill D., Waterman S.A., Gordon T.P. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand J Immunol 2004, 59:261-266.
112. Gao J., Cha S., Jonsson R., Opalko J., Peck A.B. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004, 50:2615-2621.
113. Park K., Haberberger R.V., Gordon T.P., Jackson M.W. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2011, 63:1426-1434.
114. Berg C.P., Blume K., Lauber K., Gregor M., Berg P.A., Wesselborg S., et al. Autoantibodies to muscarinic acetylcholine receptors found in patients with primary biliary cirrhosis. BMC Gastroenterol 2010, 10:120.
115. Kovacs L., Feher E., Bodnar I., Marczinovits I., Nagy G.M., Somos J., et al. Demonstration of autoantibody binding to muscarinic acetylcholine receptors in the salivary gland in primary Sjogren's syndrome. Clin Immunol 2008, 128:269-276.
116. Goin J.C., Borda E., Leiros C.P., Storino R., Sterin-Borda L. Identification of antibodies with muscarinic cholinergic activity in human Chagas' disease: pathological implications. J Auton Nerv Syst 1994, 47:45-52.
117. Magnusson Y., Marullo S., Hoyer S., Waagstein F., Andersson B., Vahlne A., et al. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990, 86:1658-1663.
118. Eftekhari P., Salle L., Lezoualc'h F., Mialet J., Gastineau M., Briand J.P., et al. Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 2000, 30:2782-2790.
119. Koo N.Y., Li J., Hwang S.M., Choi S.Y., Lee S.J., Oh S.B., et al. Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients. Rheumatology (Oxford) 2008, 47:828-833.
120. Marczinovits I., Kovacs L., Gyorgy A., Toth G.K., Dorgai L., Molnar J., et al. A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjogren's syndrome. J Autoimmun 2005, 24:47-54.
121. Kovacs L., Marczinovits I., Gyorgy A., Toth G.K., Dorgai L., Pal J., et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. Rheumatology (Oxford) 2005, 44:1021-1025.
122. Tusnady G.E., Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics 2001, 17:849-850.
123. He J., Guo J.P., Ding Y., Li Y.N., Pan S.S., Liu Y., et al. Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren's syndrome. Rheumatology (Oxford) 2011, 50:879-884.
124. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010, 69:1103-1109.
125. Nakamura Y., Wakamatsu E., Matsumoto I., Tomiita M., Kohno Y., Mori M., et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjögren syndrome. Ann Rheum Dis 2008, 67:136-137.
126. Roescher N., Kingman A., Shirota Y., Chiorini J.A., Illei G.G. Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjogren's syndrome. Ann Rheum Dis 2011, 70:235-236.
127. Dawson L.J., Allison H.E., Stanbury J., Fitzgerald D., Smith P.M. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjögren's syndrome using conventional immunological approaches. Rheumatology 2004, 43:1488-1495.